Quiz: Predicting Patient Outcomes in Ovarian Cancer

Article

How much do you know about predicting patient outcomes in ovarian cancer? Take our latest quiz to test your knowledge.

In our July ovarian cancer quiz, you’ll get a chance to test your knowledge on predicting patient outcomes in ovarian cancer. Here’s your first question:

1.  Which of the following are under investigation as potential biomarkers for early detection of ovarian cancer?

A.Circulating tumor DNA

B.Circulating microRNAs

C.Fallopian tube microRNAs

D.All of the above


Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content
Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Tim Cortese
March 26th 2025
Article

The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Vulvar Cancer Survival Discrepancies Seen in Year 1 of COVID-19 Pandemic

Roman Fabbricatore
March 19th 2025
Article

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Uterine Cancer Survival Rates Have Improved Despite Higher Mortality Risks

Russ Conroy
March 18th 2025
Article

Socioeconomic or racial disparities may contribute to unchanged overall survival among certain patients with metastatic uterine cancer.

Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.

Increased Wait Times Observed for Black/Hispanic Patients With Cervical Cancer

Roman Fabbricatore
March 18th 2025
Article

Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.